Do analysts rate DXR or STIM?

Neuronetics has a consensus price target of $4.67, indicating a potential upside of 54.02%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts plainly believe Neuronetics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Neuronetics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation & earnings, DXR or STIM?

Daxor has higher earnings, but lower revenue than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Neuronetics $149.16M 1.55 -$39M -$0.44 N/A

Is DXR or STIM more profitable?

Daxor has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Daxor's return on equity of 0.00% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Neuronetics -19.62% -125.11% -22.15%

Does the media refer more to DXR or STIM?

In the previous week, Neuronetics had 7 more articles in the media than Daxor. MarketBeat recorded 11 mentions for Neuronetics and 4 mentions for Daxor. Daxor's average media sentiment score of 0.72 beat Neuronetics' score of 0.65 indicating that Daxor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DXR or ELMD?

Electromed has a consensus target price of $43.75, indicating a potential upside of 60.55%. Given Electromed's stronger consensus rating and higher probable upside, analysts plainly believe Electromed is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Electromed 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has preferable valuation & earnings, DXR or ELMD?

Electromed has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Electromed $73.78M 3.09 $5.15M $1.31 20.80

Is DXR or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Daxor's net margin of 0.00%. Electromed's return on equity of 15.71% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Electromed 11.34% 15.71% 13.37%

Does the media prefer DXR or ELMD?

In the previous week, Daxor had 2 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Daxor and 2 mentions for Electromed. Electromed's average media sentiment score of 0.90 beat Daxor's score of 0.72 indicating that Electromed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Electromed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PROF or DXR?

Profound Medical presently has a consensus target price of $11.50, suggesting a potential upside of 92.63%. Given Profound Medical's stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, PROF or DXR?

Daxor has lower revenue, but higher earnings than Profound Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $16.10M 13.55 -$42.57M -$0.98 N/A Daxor N/A N/A N/A N/A N/A

Does the media favor PROF or DXR?

In the previous week, Profound Medical and Profound Medical both had 4 articles in the media. Daxor's average media sentiment score of 0.72 beat Profound Medical's score of 0.48 indicating that Daxor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PDEX or DXR?

Pro-Dex presently has a consensus price target of $74.00, suggesting a potential upside of 17.82%. Given Pro-Dex's stronger consensus rating and higher probable upside, research analysts plainly believe Pro-Dex is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pro-Dex 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, PDEX or DXR?

Pro-Dex has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $77.55M 2.59 $13.66M $4.13 15.21 Daxor N/A N/A N/A N/A N/A

Is PDEX or DXR more profitable?

Pro-Dex has a net margin of 17.62% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 25.13% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 17.62% 25.13% 16.02% Daxor N/A N/A N/A

Does the media prefer PDEX or DXR?

In the previous week, Pro-Dex had 4 more articles in the media than Daxor. MarketBeat recorded 8 mentions for Pro-Dex and 4 mentions for Daxor. Pro-Dex's average media sentiment score of 0.75 beat Daxor's score of 0.72 indicating that Pro-Dex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZJYL or DXR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation & earnings, ZJYL or DXR?

Jin Medical International has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jin Medical International $20.69M 7.85 $1.19M N/A N/A Daxor N/A N/A N/A N/A N/A

Is ZJYL or DXR more profitable?

Company Net Margins Return on Equity Return on Assets Jin Medical International N/A N/A N/A Daxor N/A N/A N/A

Does the media favor ZJYL or DXR?

In the previous week, Daxor had 1 more articles in the media than Jin Medical International. MarketBeat recorded 4 mentions for Daxor and 3 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.10 beat Daxor's score of 0.72 indicating that Jin Medical International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jin Medical International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Daxor (DXR) Competitors

$11.47 +0.63 (+5.81%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$11.40 -0.07 (-0.57%)

As of 09/11/2026 04:04 PM Eastern

Compare

DXR vs. STIM, ELMD, PROF, PDEX, and ZJYL

Should you buy Daxor stock or one of its competitors? Daxor's main competitors and comparable companies include Neuronetics (STIM), Electromed (ELMD), Profound Medical (PROF), Pro-Dex (PDEX), and Jin Medical International (ZJYL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Daxor compare to Neuronetics?

Daxor (NASDAQ:DXR) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Neuronetics had 7 more articles in the media than Daxor. MarketBeat recorded 11 mentions for Neuronetics and 4 mentions for Daxor. Daxor's average media sentiment score of 0.72 beat Neuronetics' score of 0.65 indicating that Daxor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.3% of Daxor shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Daxor has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Neuronetics has a consensus price target of $4.67, indicating a potential upside of 54.02%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts plainly believe Neuronetics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Daxor has higher earnings, but lower revenue than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Neuronetics	$149.16M	1.55	-$39M	-$0.44	N/A

Daxor has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Daxor's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Neuronetics	-19.62%	-125.11%	-22.15%

Summary

Neuronetics beats Daxor on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to Electromed?

Daxor (NASDAQ:DXR) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Electromed has a net margin of 11.34% compared to Daxor's net margin of 0.00%. Electromed's return on equity of 15.71% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Electromed	11.34%	15.71%	13.37%

In the previous week, Daxor had 2 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Daxor and 2 mentions for Electromed. Electromed's average media sentiment score of 0.90 beat Daxor's score of 0.72 indicating that Electromed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Electromed has a consensus target price of $43.75, indicating a potential upside of 60.55%. Given Electromed's stronger consensus rating and higher probable upside, analysts plainly believe Electromed is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Daxor has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Electromed has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Electromed has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Electromed	$73.78M	3.09	$5.15M	$1.31	20.80

1.3% of Daxor shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Electromed beats Daxor on 10 of the 12 factors compared between the two stocks.

How does Daxor compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profound Medical presently has a consensus target price of $11.50, suggesting a potential upside of 92.63%. Given Profound Medical's stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to Profound Medical's net margin of -171.57%. Daxor's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
Daxor	N/A	N/A	N/A

In the previous week, Profound Medical and Profound Medical both had 4 articles in the media. Daxor's average media sentiment score of 0.72 beat Profound Medical's score of 0.48 indicating that Daxor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Daxor has lower revenue, but higher earnings than Profound Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	13.55	-$42.57M	-$0.98	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Profound Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

Summary

Profound Medical beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Pro-Dex presently has a consensus price target of $74.00, suggesting a potential upside of 17.82%. Given Pro-Dex's stronger consensus rating and higher probable upside, research analysts plainly believe Pro-Dex is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Comparatively, 51.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pro-Dex has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Pro-Dex has a net margin of 17.62% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 25.13% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	17.62%	25.13%	16.02%
Daxor	N/A	N/A	N/A

In the previous week, Pro-Dex had 4 more articles in the media than Daxor. MarketBeat recorded 8 mentions for Pro-Dex and 4 mentions for Daxor. Pro-Dex's average media sentiment score of 0.75 beat Daxor's score of 0.72 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pro-Dex has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.59	$13.66M	$4.13	15.21
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

Pro-Dex beats Daxor on 10 of the 12 factors compared between the two stocks.

How does Daxor compare to Jin Medical International?

Jin Medical International (NASDAQ:ZJYL) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

1.3% of Daxor shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Jin Medical International has a beta of 7.31, meaning that its stock price is 631% more volatile than the broader market. Comparatively, Daxor has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

In the previous week, Daxor had 1 more articles in the media than Jin Medical International. MarketBeat recorded 4 mentions for Daxor and 3 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.10 beat Daxor's score of 0.72 indicating that Jin Medical International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jin Medical International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Jin Medical International	N/A	N/A	N/A
Daxor	N/A	N/A	N/A

Jin Medical International has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jin Medical International	$20.69M	7.85	$1.19M	N/A	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

Daxor beats Jin Medical International on 5 of the 8 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.96M	$5.48B	$7.17B	$12.85B
Dividend Yield	N/A	1.79%	2.57%	11.71%
P/E Ratio	N/A	25.09	274.94	25.27
Price / Sales	N/A	71.54	633.23	90.48
Price / Cash	N/A	32.57	76.65	51.52
Price / Book	N/A	5.97	10.33	6.20
Net Income	N/A	$150.75M	$3.50B	$358.50M
7 Day Performance	11.68%	-2.83%	-3.32%	-2.35%
1 Month Performance	12.45%	-3.09%	-0.41%	-2.77%
1 Year Performance	-1.63%	9.34%	19.21%	7.63%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	1.3165 of 5 stars	$11.47 +5.8%	N/A	+3.2%	$66.96M	N/A	N/A	37	Short Interest Increase High Trading Volume
STIM Neuronetics	3.8937 of 5 stars	$3.09 +2.5%	$4.67 +51.3%	-12.4%	$234.93M	$149.16M	N/A	180	News Coverage Analyst Forecast Gap Up
ELMD Electromed	3.2507 of 5 stars	$27.30 +2.4%	$43.75 +60.3%	+8.7%	$225.61M	$73.78M	35.96	160
PROF Profound Medical	2.58 of 5 stars	$6.04 +1.3%	$11.50 +90.5%	+50.8%	$223.56M	$16.10M	N/A	150	Analyst Downgrade Gap Up High Trading Volume
PDEX Pro-Dex	3.291 of 5 stars	$59.57 -0.5%	$74.00 +24.2%	+78.5%	$190.11M	$77.55M	14.38	140	News Coverage Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors